Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of lurbinectedin alone or with gemcitabine versus docetaxel in second-line unresectable NSCLC
2013-000548-25Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Apr 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lurbinectedin in non-small cell lung cancer (NSCLC) (3 arms), sponsored by PharmaMar. Primary endpoint: Progression-free survival rate at four months. Started Apr 2013; status: completed.
02
Drugs
lurbinectedin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2013-000548-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000548-25.